TheraCryf PLC
8EV
Company Profile
Business description
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
Chart of the Week: Booming mined commodity prices see little value on offer
Iran War disruptions drive thermal coal and aluminum prices higher but value to be found in other pockets.
stocks
A deleted disclosure in SpaceX’s IPO filing shows its AI infrastructure as a cash cow
SpaceX could recoup its AI infrastructure capex in under a month.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,945.20 | 66.70 | 0.75% |
| CAC 40 | 8,207.89 | 34.78 | 0.43% |
| DAX 40 | 25,177.80 | 7.09 | -0.03% |
| Dow JONES (US) | 50,644.28 | 182.60 | 0.36% |
| FTSE 100 | 10,505.01 | 13.62 | 0.13% |
| HKSE | 25,328.23 | 271.22 | -1.06% |
| NASDAQ | 26,674.73 | 18.55 | 0.07% |
| Nikkei 225 | 64,999.41 | 3.32 | 0.01% |
| NZX 50 Index | 13,252.13 | 24.32 | 0.18% |
| S&P 500 | 7,520.36 | 1.24 | 0.02% |
| S&P/ASX 200 | 8,717.70 | 65.50 | 0.76% |
| SSE Composite Index | 4,093.73 | 51.65 | -1.25% |